Specifically, HIF-2α inhibition combined with ICB promoted Th1 CD4+ T cells that can favor activation and phagocytic functions of microglia and macrophages through IFNγ, also reported for GBM in the context of CTLA-4 blockade [12]. The gene discussed is CD4; the disease is glioblastoma.